News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
33,981 Results
Type
Article (1296)
Company Profile (3)
Press Release (32682)
Section
Business (15439)
Career Advice (98)
Deals (1945)
Drug Development (3699)
FDA (519)
Job Trends (677)
News (20600)
Policy (1009)
Tag
Academia (46)
Accelerated approval (1)
Adcomms (1)
Allergies (4)
Alliances (1079)
ALS (5)
Alzheimer's disease (80)
Antibody-drug conjugate (ADC) (5)
Approvals (551)
Artificial intelligence (8)
Autoimmune disease (1)
Automation (1)
Bankruptcy (13)
Best Places to Work (659)
BIOSECURE Act (1)
Biosimilars (9)
Biotechnology (3)
Bladder cancer (17)
Breast cancer (30)
Cancer (233)
Cardiovascular disease (20)
Career advice (98)
CAR-T (8)
Cell therapy (16)
Cervical cancer (1)
Clinical research (3342)
Collaboration (39)
Compensation (11)
COVID-19 (65)
CRISPR (2)
C-suite (4)
Cystic fibrosis (4)
Data (410)
Depression (13)
Diabetes (18)
Diagnostics (279)
Digital health (4)
Drug discovery (7)
Drug pricing (3)
Duchenne muscular dystrophy (9)
Earnings (14497)
Editorial (1)
Events (4973)
Executive appointments (13)
FDA (783)
Fibrodysplasia Ossificans Progressiva (2)
Frontotemporal dementia (3)
Funding (23)
Gene editing (2)
Generative AI (2)
Gene therapy (18)
GLP-1 (34)
Government (94)
Guidances (159)
Healthcare (888)
HIV (3)
Huntington's disease (2)
IgA nephropathy (13)
Immunology and inflammation (12)
Immuno-oncology (2)
Indications (7)
Infectious disease (77)
Inflammatory bowel disease (5)
Influenza (3)
Intellectual property (6)
Interviews (9)
IPO (1451)
Job creations (55)
Job search strategy (94)
Labor market (3)
Layoffs (14)
Legal (148)
Liver cancer (3)
Lung cancer (39)
Lymphoma (36)
Manufacturing (13)
MASH (14)
Medical device (805)
Medtech (811)
Mergers & acquisitions (532)
Metabolic disorders (53)
Multiple sclerosis (5)
NASH (1)
Neurodegenerative disease (6)
Neuropsychiatric disorders (8)
Neuroscience (136)
NextGen: Class of 2025 (184)
Non-profit (59)
Now hiring (1)
Obesity (22)
Opinion (3)
Ovarian cancer (4)
Pain (7)
Pancreatic cancer (11)
Parkinson's disease (9)
Patents (15)
Patient recruitment (11)
Peanut (2)
People (1063)
Pharmacy benefit managers (1)
Phase I (732)
Phase II (1380)
Phase III (1475)
Pipeline (620)
Policy (2)
Postmarket research (182)
Preclinical (325)
Press Release (1)
Prostate cancer (11)
Psychedelics (4)
Radiopharmaceuticals (5)
Rare diseases (20)
Real estate (145)
Regulatory (905)
Reports (5)
Research institute (45)
Resumes & cover letters (5)
RSV (5)
Schizophrenia (12)
Series A (3)
Sickle cell disease (1)
Special edition (1)
Spinal muscular atrophy (2)
Sponsored (3)
Startups (83)
Supply chain (2)
Vaccines (16)
Venture capital (3)
Weight loss (12)
Women's health (5)
Date
Today (1)
Last 7 days (26)
Last 30 days (108)
Last 365 days (2083)
2025 (2056)
2024 (2310)
2023 (2522)
2022 (2764)
2021 (2908)
2020 (2353)
2019 (1780)
2018 (1322)
2017 (1101)
2016 (786)
2015 (1160)
2014 (737)
2013 (443)
2012 (514)
2011 (556)
2010 (581)
Location
Africa (102)
Alabama (6)
Arizona (17)
Arkansas (1)
Asia (2255)
Australia (269)
California (727)
Canada (196)
China (44)
Colorado (49)
Connecticut (41)
Delaware (29)
Europe (4140)
Florida (98)
Georgia (31)
Illinois (56)
India (2)
Indiana (44)
Japan (29)
Kansas (4)
Kentucky (2)
Louisiana (7)
Maine (6)
Maryland (79)
Massachusetts (446)
Michigan (18)
Minnesota (37)
Mississippi (1)
Missouri (7)
Montana (3)
Nevada (4)
New Hampshire (6)
New Jersey (261)
New Mexico (1)
New York (161)
North Carolina (102)
Northern California (359)
Ohio (15)
Pennsylvania (156)
Puerto Rico (1)
South America (108)
South Carolina (1)
Southern California (280)
Tennessee (8)
Texas (71)
United States (2558)
Utah (25)
Virginia (11)
Washington D.C. (3)
Washington State (75)
Wisconsin (5)
33,981 Results for "104".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Quoin Pharmaceuticals Announces Private Placement Financing of Up to $104.5 Million
October 13, 2025
·
8 min read
Press Releases
Tharimmune Receives Positive FDA Feedback for TH104 Prophylaxis Program Against Respiratory Depression from Fentanyl and Ultrapotent Opioids
November 14, 2025
·
5 min read
Press Releases
MAIA Biotechnology Announces First Patient Dosed in THIO-104 Phase 3 Pivotal Trial Evaluating Ateganosine as Third-Line Treatment for Advanced Non-Small Cell Lung Cancer
December 12, 2025
·
6 min read
Press Releases
Eupraxia Pharmaceuticals Reports Additional 52-week Follow-up Data from the RESOLVE Trial in Eosinophilic Esophagitis (EoE) Demonstrating Consistent Results after Dosing with EP-104GI
November 14, 2025
·
11 min read
Press Releases
Grace Therapeutics Granted Sixth U.S. Patent Covering I.V. Dosing Regimen for GTx-104
September 18, 2025
·
8 min read
Press Releases
Eleva advances CPV-104 into Phase 1b clinical testing in patients with C3G, following the successful completion of single ascending dose evaluation in healthy volunteers
October 21, 2025
·
3 min read
Press Releases
Grace Therapeutics Announces U.S. Food and Drug Administration Acceptance for Review of New Drug Application for GTx-104
August 28, 2025
·
9 min read
Press Releases
Tharimmune Announces Upcoming Conference Presentations Highlighting Lead Asset TH104, A New Formulation Against Ultrapotent Opioids and Fentanyl
September 5, 2025
·
3 min read
Press Releases
Reunion Neuroscience Announces First Patient Dosed in REKINDLE Phase 2 Clinical Trial of RE104 for the Treatment of Adjustment Disorder (AjD) in Cancer and Other Medical Illnesses
October 1, 2025
·
5 min read
Press Releases
Reunion Neuroscience Announces Final Closing of its Series A Financing and Plans to Advance RE104 into Clinical Development for the Treatment of Generalized Anxiety Disorder (GAD)
September 17, 2025
·
5 min read
1 of 3,399
Next
